Treatment-experienced people: latest news

Treatment-experienced people resources

  • Side-effects

    The booklet provides information about possible side-effects of HIV treatment. ...

    From: Booklets

    Information level Level 2
  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Antiretroviral drugs chart

    A one-page reference guide to the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions....

    From: Antiretroviral drugs chart

    Information level Level 1
  • Anti-HIV drugs

    This booklet is a starting point for anyone who wants to know about the drugs used in HIV treatment. ...

    From: Booklets

    Information level Level 2

Treatment-experienced people features

Treatment-experienced people in your own words

Treatment-experienced people news from aidsmap

More news

Treatment-experienced people news selected from other sources

  • Antibody-Based HIV Tx Proves Durable

    The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

    10 October 2017 | MedPage Today
  • People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

    Ibalizumab is a new drug that is effective against drug resistant HIV. It is not approved for sale in the United States, but patients can take advantage of an expanded access program to start treatment right away.

    15 December 2016 |
  • Exploring possible treatment options after virological failure with raltegravir

    In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

    21 January 2015 | CATIE
  • Janssen to Stop Offering "Virtual Phenotype" Testing, and Musings on Progress

    As is plainly obvious to anyone doing HIV care, the incidence of new patients with the sort of HIV drug resistance for which the test was developed has plummeted. There simply aren't many new patients out there who have multiple mutations, especially in the PI-drug class, and who will need the computational black-box firepower provided by a vircoTYPE.

    27 November 2013 | The BodyPRO
  • Second- and Third-Line ART Cost 24% and 41% More Than First Line in US

    Second-line antiretroviral therapy (ART) costs 24% more per year than first-line therapy in the United States, and third-line therapy costs 41% more than first-line therapy, according to a large insurance claims-based analysis.

    17 September 2013 | NATAP
  • No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial

    After 48 weeks of the randomized TEACH trial, virologic responses were equivalent when antiretroviral-experienced people took standard-dose etravirine with 300/100 or 400/100 mg of atazanavir/ritonavir daily.

    22 July 2013 | NATAP
  • Third-line ARVs could widen treatment gap in Zimbabwe

    HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.

    12 March 2013 | IRIN Plus News
  • Redefining Expanded Access Programs for patients with MDR-HIV

    It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

    04 December 2012 | GMHC Treatment Issues
  • Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

    HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

    13 November 2012 | International AIDS Society
  • Mutation breaks HIV's resistance to drugs

    The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

    14 September 2012 | Science Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.